CN1902326A - 用于癌症诊断和治疗的差异性表达的肿瘤特异性多肽 - Google Patents

用于癌症诊断和治疗的差异性表达的肿瘤特异性多肽 Download PDF

Info

Publication number
CN1902326A
CN1902326A CNA200480034085XA CN200480034085A CN1902326A CN 1902326 A CN1902326 A CN 1902326A CN A200480034085X A CNA200480034085X A CN A200480034085XA CN 200480034085 A CN200480034085 A CN 200480034085A CN 1902326 A CN1902326 A CN 1902326A
Authority
CN
China
Prior art keywords
cancer
protein
immunogenic membrane
steroid
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480034085XA
Other languages
English (en)
Chinese (zh)
Inventor
T·布施曼
N·-K·福蒂亚迪斯
M·福赫斯
S·黑姆
T·伊利尼亚
S·拉默
J·莫伊尔
K·罗特曼-科西克
V·塞伯特
S·T·佩雷斯
K·斯戴荘斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of CN1902326A publication Critical patent/CN1902326A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA200480034085XA 2003-09-18 2004-09-20 用于癌症诊断和治疗的差异性表达的肿瘤特异性多肽 Pending CN1902326A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03090307.4 2003-09-18
EP03090307 2003-09-18
US51207803P 2003-10-20 2003-10-20
US60/512,078 2003-10-20

Publications (1)

Publication Number Publication Date
CN1902326A true CN1902326A (zh) 2007-01-24

Family

ID=37657558

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480034085XA Pending CN1902326A (zh) 2003-09-18 2004-09-20 用于癌症诊断和治疗的差异性表达的肿瘤特异性多肽

Country Status (10)

Country Link
US (1) US20090252721A1 (enExample)
EP (2) EP1673470A2 (enExample)
JP (1) JP2007521015A (enExample)
CN (1) CN1902326A (enExample)
AU (1) AU2004272747A1 (enExample)
BR (1) BRPI0414446A (enExample)
CA (1) CA2539490A1 (enExample)
IL (1) IL174047A0 (enExample)
SG (1) SG146622A1 (enExample)
WO (1) WO2005026735A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102395682A (zh) * 2007-09-06 2012-03-28 生物治疗诊断股份有限公司 肿瘤分级和癌症预后
CN104204805A (zh) * 2012-03-14 2014-12-10 萨克生物研究学院 腺病毒肿瘤诊断法
CN109646685A (zh) * 2017-10-12 2019-04-19 北京医院 stomatin蛋白及其编码基因在肺癌诊断治疗中的应用
CN111394370A (zh) * 2020-03-03 2020-07-10 华南农业大学 一种猪RagA基因及其应用
CN114540349A (zh) * 2020-11-27 2022-05-27 中国科学院分子细胞科学卓越创新中心 结合yb-1蛋白的核酸分子
CN116482367A (zh) * 2023-05-04 2023-07-25 中国中医科学院望京医院(中国中医科学院骨伤科研究所) 一种联合mSEPT9检测和生物标志物的结直肠癌检测方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2599875A1 (en) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
WO2006127976A2 (en) * 2005-05-24 2006-11-30 Isis Pharmaceuticals, Inc. Compositions and their uses directed to ptpru
DE602006015508D1 (de) * 2005-11-16 2010-08-26 Pantarhei Bioscience Bv Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs
US20100028335A1 (en) * 2007-02-02 2010-02-04 Novartis Ag Compositions and Methods to Treat Bone Related Disorders
US20080299138A1 (en) * 2007-05-25 2008-12-04 Duffy Karen E Toll-Like Receptor 3 Modulators and Uses Thereof
US8158373B2 (en) * 2008-03-25 2012-04-17 Case Western Reserve University Method of detecting cancer and evaluating cancer prognosis
WO2010056993A2 (en) * 2008-11-14 2010-05-20 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential
WO2010075521A1 (en) * 2008-12-23 2010-07-01 Case Western Reserve University Compositions and methods of treating cancer
US8940826B2 (en) 2009-07-16 2015-01-27 Omnova Solutions Inc. Protective coating compositions
MY166040A (en) 2010-09-15 2018-05-21 Almac Diagnostics Ltd Molecular diagnostic test for cancer
EP2809800A1 (en) 2012-01-30 2014-12-10 VIB vzw Means and method for diagnosis and treatment of alzheimer's disease
JP6327662B2 (ja) * 2012-09-26 2018-05-23 学校法人藤田学園 細胞表面タンパクを抗原とする抗体を測定する方法
WO2016080830A2 (en) * 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
JP2023518976A (ja) 2020-03-23 2023-05-09 エイチディーティー バイオ コーポレーション Rnaを送達するための組成物および方法
AU2022351009A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Rna vaccines against infectious diseases
WO2023048758A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Dried nanoparticle compositions
KR20240099177A (ko) 2021-09-22 2024-06-28 에이치디티 바이오 코포레이션 SARS-CoV-2 RNA 백신 조성물 및 사용 방법
KR20240111819A (ko) 2021-09-22 2024-07-17 에이치디티 바이오 코포레이션 암 치료 조성물 및 이들의 용도

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0003415A3 (en) 1978-01-20 1979-08-22 Glaxo Group Limited Beta-lactam compounds, processes for their preparation,compositions containing them and intermediates of use in their preparation
US4843000A (en) 1979-12-26 1989-06-27 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4849338A (en) 1982-07-16 1989-07-18 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4520110A (en) 1981-10-06 1985-05-28 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing a phycobiliprotein labeled ligand or receptor
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4542104A (en) 1983-04-06 1985-09-17 The Board Of Trustees Of The Leland Stanford Jr. Univ. Phycobiliprotein fluorescent conjugates
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9705949D0 (en) 1997-03-21 1997-05-07 Electrophoretics International Diagnosis of tumours and other abnormalities of body cells
US6197543B1 (en) * 1997-10-28 2001-03-06 Incyte Pharmaceuticals, Inc. Human vesicle membrane protein-like proteins
US6902898B2 (en) * 1998-11-16 2005-06-07 National Institute Of Advanced Industrial Science And Technology Human derived bradeion proteins, DNA coding for the proteins, and uses thereof
EP1033404A1 (en) * 1999-01-29 2000-09-06 F. Hoffmann-La Roche Ag New gene with down-regulated expression in metastatic human melanoma cells
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
CA2384713A1 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US20030104413A1 (en) * 2000-07-14 2003-06-05 Tang Y. Tom Novel Nucleic acids and polypeptides
US20030108926A1 (en) * 2000-03-15 2003-06-12 Eos Biotechnology, Inc. Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
JP2004512023A (ja) * 2000-06-09 2004-04-22 コリクサ コーポレイション 結腸癌の治療および診断のための組成物および方法
AU2001285047A1 (en) * 2000-08-16 2002-02-25 Chiron Corporation Human genes and gene expression products
US20030134283A1 (en) * 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
WO2003029273A2 (en) * 2001-09-28 2003-04-10 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
EP1308459A3 (en) * 2001-11-05 2003-07-09 Research Association for Biotechnology Full-length cDNA sequences
AU2003304203A1 (en) * 2002-10-29 2005-01-04 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102395682A (zh) * 2007-09-06 2012-03-28 生物治疗诊断股份有限公司 肿瘤分级和癌症预后
CN104204805A (zh) * 2012-03-14 2014-12-10 萨克生物研究学院 腺病毒肿瘤诊断法
CN104204805B (zh) * 2012-03-14 2017-08-01 萨克生物研究学院 腺病毒肿瘤诊断法
CN109646685A (zh) * 2017-10-12 2019-04-19 北京医院 stomatin蛋白及其编码基因在肺癌诊断治疗中的应用
CN111394370A (zh) * 2020-03-03 2020-07-10 华南农业大学 一种猪RagA基因及其应用
CN111394370B (zh) * 2020-03-03 2022-03-25 华南农业大学 一种猪RagA基因及其应用
CN114540349A (zh) * 2020-11-27 2022-05-27 中国科学院分子细胞科学卓越创新中心 结合yb-1蛋白的核酸分子
CN116482367A (zh) * 2023-05-04 2023-07-25 中国中医科学院望京医院(中国中医科学院骨伤科研究所) 一种联合mSEPT9检测和生物标志物的结直肠癌检测方法

Also Published As

Publication number Publication date
US20090252721A1 (en) 2009-10-08
SG146622A1 (en) 2008-10-30
WO2005026735A2 (en) 2005-03-24
JP2007521015A (ja) 2007-08-02
CA2539490A1 (en) 2005-03-24
IL174047A0 (en) 2006-08-01
BRPI0414446A (pt) 2006-11-14
WO2005026735A3 (en) 2005-11-03
EP1673470A2 (en) 2006-06-28
EP2050827A3 (en) 2009-09-02
EP2050827A2 (en) 2009-04-22
AU2004272747A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
US12084723B2 (en) Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
CN1902326A (zh) 用于癌症诊断和治疗的差异性表达的肿瘤特异性多肽
JP5934093B2 (ja) 子宮内膜がんのマーカー
JP6581247B2 (ja) 前立腺癌の診断および処置におけるマーカーの使用
WO2005100998A2 (en) Membrane markers for use in cancer diagnosis and therapy
JP2010525301A (ja) 子宮内膜癌および前癌の診断、分類および治療の方法
US20140315743A1 (en) Methods and Compositions for the Treatment and Diagnosis of Ovarian Cancer
US20160208335A1 (en) Use of RhoA in Cancer Diagnosis and Inhibitor Screening
JP2004503238A (ja) 結腸癌に関するポリヌクレオチド
CN101405392A (zh) 一种新型的doublecortin样激酶基因mRNA剪接异构体及其在神经外胚层起源癌症的诊断和治疗中的应用
WO2012029722A1 (ja) スクリーニング方法
CA2773614A1 (en) Method of treating cancer by inhibiting trim59 expression or activity
AU2005246090A1 (en) STAMP2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2004072285A1 (en) “goblin” cancer associated polypeptides, related reagents, and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070124